Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11646556 | 0.82 | — | — | |
| SCHEMBL10537680 | 0.78 | MEN1 (0.34) | MEN1KMT2ASLC6A4SLC6A2SMN1; SMN2 | |
| SCHEMBL6844350 | 0.77 | — | — | |
| SCHEMBL8007596 | 0.76 | MEN1 (0.33) | MEN1KMT2ASLC6A4SLC6A2SMN1; SMN2 | |
| SCHEMBL431808 | 0.76 | OPRD1 (0.36) | MEN1KMT2ASLC6A4SLC6A2SMN1; SMN2 | |
| SCHEMBL3533330 | 0.76 | OPRD1 (0.36) | MEN1KMT2ASLC6A4SLC6A2SMN1; SMN2 | |
| SCHEMBL1744094 | 0.75 | MEN1 (0.39) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6956721 | 0.74 | SMN1; SMN2 (0.38) | MEN1KMT2ASLC6A4SLC6A2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6960637 | 0.73 | SMN1; SMN2 (0.33) | MEN1KMT2ASLC6A4SLC6A2SMN1; SMN2 | |
| SCHEMBL20755803 | 0.73 | SMN1; SMN2 (0.37) | MEN1KMT2ASLC6A4SLC6A2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846677-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-8772285-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-07-08 | — | — | US | disclosed |
| US-8501739-B2 | Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-06 | — | — | US | disclosed |
| CN-103110635-A | Histamine H3 receptor antagonist | NOVO NORDISK AS | 2013-05-22 | — | — | CN | disclosed |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | VTVX HOLDINGS II LLC | 2013-03-28 | — | — | US | disclosed |
| US-8394842-B2 | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120232078-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2386554-A1 | Compounds active at the histamine H3 receptor | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| CN-101410385-B | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS LLC | 2011-08-24 | — | — | CN | disclosed |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HIGH POINT PHARMACEUTICALS, LLC | 2010-11-25 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2233470-A1 | Histamine H3 receptor antagonists | High Point Pharmaceuticals, LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| CN-101795567-A | New heteocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS LLC | 2010-08-04 | — | — | CN | disclosed |
| US-20090312309-A1 | Novel Medicaments | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-12-17 | — | — | US | disclosed |
| CN-101410385-A | Benzothiazoles having histamine H3 receptor activity | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-04-15 | — | — | CN | disclosed |
| EP-2014656-A2 | New heteocyclic h3 antagonists | TRANSTECH PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| CN-101218206-A | Histamine H3 receptor antagonists | NOVO NORDISK AS (DK) | 2008-07-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232078-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | MEN1 862/4885KMT2A 1116/4885SLC6A4 948/4885 |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HRH3, HRH4, HRH2 | MEN1 3067/4885KMT2A 865/4885SLC6A4 1081/4885 |
| US-20100298316-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | MEN1 3222/4885KMT2A 249/4885SLC6A4 1367/4885 |
| US-20090312309-A1 | Novel Medicaments | HRH3, HRH4, HRH1 | MEN1 862/4885KMT2A 1116/4885SLC6A4 948/4885 |
| US-20130079340-A1 | Benzothiazoles Having Histamine H3 Receptor Activity | HRH3, HRH2, HRH4 | MEN1 3980/4885KMT2A 189/4885SLC6A4 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.